Robert M. Kotin BA, PhD
Dr. Robert Kotin, also known as Rob, Ph.D. serves as Vice President of Production at Voyager Therapeutics, Inc. Dr. Kotin served as the Head of Molecular Hematology at the National Heart, Lung and Blood Institute of the National Institute of Health (NIH) in Washington, D.C. Dr. Kotin's work on Adeno-Associated Viruses (AAV) form the basis for the use of AAV in genetherapy. He is considered to be a leading expert in the field of AAV virology and genetherapy.
He is a preeminent expert in AAV gene therapy manufacturing and the co-inventor of the baculovirus-based AAV production system. He joined Voyager from the National Heart, Lung and Blood Institute of the National Institutes of Health, where he served for more than 20 years in roles of increasing responsibility, as Senior Investigator and Laboratory Chief. Previously, Dr. Kotin served as head of the AAV gene therapy program at Genetic Therapy and as Senior Research Scientist of the Medical Research Division at Lederle Laboratories. He served as a Member of the Scientific Advisory Council of MediGene AG.
He was a Norman and Rosita Winston Foundation research fellow from 1986 to 1988 and a research associate at Cornell University Medical College from 1989 to 1990. Dr. Kotin has authored or co-authored more than 75 papers and is an inventor on 10 U.S. patents. He was an associate editor for the Journal of Gene Medicine and serves on the editorial boards of Gene Therapy and Human Gene Therapy. Dr. Kotin holds a B.A. in biology from the University of California, Santa Cruz and a Ph.D. in microbiology from Rutgers University and the University of Medicine and Dentistry of New Jersey.